Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Dan ZhaoHaiqing LiIsa MambetsarievTamara MirzapoiazovaChen ChenJeremy FrickePrakash KulkarniVictoria VillaflorLeonidas ArvanitisStanley HamiltonMichelle AfkhamiRaju PillaiBrian ArmstrongLoretta EhrunmwunseeErminia MassarelliMartin SattlerArya AminiRavi SalgiaPublished in: Cancers (2022)
KRAS mutation subtypes such as G12D and comutations such as CDKN2/A and MET may modulate the immunotherapy responses and outcomes in lung cancer.